ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era.The Journal of antimicrobial chemotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the safety of resuming antitumor therapy in tumor patients infected with COVID-19.
methodsWe collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded. Primary endpoints included the incidence of AEs and re-infection of COVID-19. The secondary endpoints included the incidence and duration of COVID-19 related symptoms.
resultsThe most common COVID-19 symptoms were fever (39.5%), cough (37.2%), and fatigue (44.2%). Most patients' symptoms lasted no more than a week Two patients were re-infected with COVID-19. All-grade AEs with an incidence rate > 10% included anemia, increased gamma-glutamyl transferase (GGT), anorexia, neutropenia, hypocalcemia, leukopenia, thrombocytopenia, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, and nausea. Grade 3-4 AEs with an incidence rate higher than 5% included anemia, neutropenia, leukopenia, thrombocytopenia, anorexia, and vomiting. The incidence of AEs before and after COVID-19 infection did not show a significant difference.
conclusionResuming antitumor therapy early after SARS-CoV-2 test turned negative did not increase antitumor therapy-related AEs or the incidence of re-infection in COVID-19 infection patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.